Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**HERAMED LIMITED**
ABN	**65 626 295 314**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Timothy Chapman
Date of last notice	27 April 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Inverness Capital Pty Ltd <Match Partner Investment A/C> of which Tim Chapman is a director and a shareholder of the trustee and a beneficiary of the trust
Date of change	9 June 2026
No. of securities held prior to change Inverness Capital Pty Ltd <Match Partner Investment A/C> of which Tim Chapman is a Director and a shareholder of the trustee and a beneficiary of the trust	- 5,277,778 fully paid ordinary shares - 3,666,666 unlisted options with an exercise price of $0.12 and an expiry of 20/07/2026 - 4,500,000 unlisted options with an exercise price of $0.045 and an expiry of 11/03/2027 - 5,000,000 unlisted options with an exercise price of $0.02 expiring 26/06/2028 - 2,500,000 Performance Rights

<table>
<tr><td>Class</td><td>
<table>
<tr><th>Number of Performance Rights</th><th>Vesting Condition</th><th>Exercise Date – Exercise no later than</th></tr>
<tr><td>700,000</td><td>20 day VWAP of $0.08 (8 cents) on or before the date that is 12 months from issue.</td><td>18 months from vesting</td></tr>
<tr><td>700,000</td><td>20 day VWAP of $0.12 (12 cents) on or before the date that is 24 months from issue.</td><td>18 months from vesting</td></tr>
<tr><td>700,000</td><td>The Company announcing to ASX that HeraCARE has reached not less than 2,000 active paid users at any time on or before 31 December 2027.</td><td>18 months from vesting</td></tr>
<tr><td>700,000</td><td>The Company announcing to ASX that HeraCARE has reached not less than 8,000 active paid users at any time on or before 31 December 2028.</td><td>18 months from vesting</td></tr>
<tr><td>700,000</td><td>The Company announcing to ASX that HeraCARE has reached not less than 20,000 active paid users at any time on or before 31 December 2029.</td><td>18 months from vesting</td></tr>
</table>
</td></tr>
<tr><td>Number acquired</td><td>3,500,000 Performance Rights</td></tr>
<tr><td>Number disposed</td><td>Nil</td></tr>
<tr><td>Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation</td><td>Refer to AGM Notice of Meeting dated 21 April 2026.</td></tr>
<tr><td>No. of securities held after change</td><td>- 5,277,778 fully paid ordinary shares
- 3,666,666 unlisted options with an exercise price of $0.12 and an expiry of 20/07/2026
- 4,500,000 unlisted options with an exercise price of $0.045 and an expiry of 11/03/2027
- 5,000,000 unlisted options with an exercise price of $0.02 expiring 26/06/2028
- 6,000,000 Performance Rights</td></tr>
<tr><td>Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</td><td>Issue of Performance Rights as approved at the Annual General Meeting on 21 May 2026.</td></tr>
</table>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HERAMED LIMITED
ABN	65 626 295 314

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	ANOUSHKA GUNGADIN
Date of last notice	16 March 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	9 June 2026
No. of securities held prior to change ANOUSHKA GUNGADIN	- 2,633,860 Ordinary Fully Paid Shares - 850,000 Unlisted Options with an exercise price of $0.1358 expiring 28/07/2027 - 5,000,000 Unlisted Options with an exercise price of $0.02 expiring 26/06/2028 - 13,166,140 Performance Rights
Class	

Number of Performance Rights	Vesting Condition	Exercise Date – Exercise no later than
1,900,000	20 day VWAP of $0.08 (8 cents) on or before the date that is 12 months from issue.	18 months from vesting
1,900,000	20 day VWAP of $0.12 (12 cents) on or before the date that is 24 months	18 months from vesting

		from issue.	
	1,900,000	The Company announcing to ASX that HeraCARE has reached not less than 2,000 active paid users at any time on or before 31 December 2027.	18 months from vesting
	1,900,000	The Company announcing to ASX that HeraCARE has reached not less than 8,000 active paid users at any time on or before 31 December 2028.	18 months from vesting
	1,900,000	The Company announcing to ASX that HeraCARE has reached not less than 20,000 active paid users at any time on or before 31 December 2029.	18 months from vesting

Number acquired	9,500,000 Performance Rights
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Refer to AGM Notice of Meeting dated 21 April 2026.
No. of securities held after change	- 2,633,860 Ordinary Fully Paid Shares - 850,000 Unlisted Options with an exercise price of $0.1358 expiring 28/07/2027 - 5,000,000 Unlisted Options with an exercise price of $0.02 expiring 26/06/2028 - 22,666,140 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights as approved at the Annual General Meeting on 21 May 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**HERAMED LIMITED**
ABN	**65 626 295 314**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Hinton
Date of last notice	27 April 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct/ Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	David Ayers Hinton and Heather Joy Hinton <Bromilow Account> of which Mr Hinton is a trustee and beneficiary
Date of change	9 June 2026
No. of securities held prior to change David Ayers Hinton and Heather Joy Hinton <Bromilow Account> of which Mr Hinton is a trustee and beneficiary	- 430,000 Ordinary Fully Paid Shares - 3,000,000 unlisted options with an exercise price of $0.02 expiring 26/06/2028 - 1,500,000 Performance Rights

<table>
<tr><td>Class</td><td>
<table>
<tr><th>Number of Performance Rights</th><th>Vesting Condition</th><th>Exercise Date – Exercise no later than</th></tr>
<tr><td>400,000</td><td>20 day VWAP of $0.08 (8 cents) on or before the date that is 12 months from issue.</td><td>18 months from vesting</td></tr>
<tr><td>400,000</td><td>20 day VWAP of $0.12 (12 cents) on or before the date that is 24 months from issue.</td><td>18 months from vesting</td></tr>
<tr><td>400,000</td><td>The Company announcing to ASX that HeraCARE has reached not less than 2,000 active paid users at any time on or before 31 December 2027.</td><td>18 months from vesting</td></tr>
<tr><td>400,000</td><td>The Company announcing to ASX that HeraCARE has reached not less than 8,000 active paid users at any time on or before 31 December 2028.</td><td>18 months from vesting</td></tr>
<tr><td>400,000</td><td>The Company announcing to ASX that HeraCARE has reached not less than 20,000 active paid users at any time on or before 31 December 2029.</td><td>18 months from vesting</td></tr>
</table>
</td></tr>
<tr><td>Number acquired</td><td>2,000,000 Performance Rights</td></tr>
<tr><td>Number disposed</td><td>Nil</td></tr>
<tr><td>Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation</td><td>Refer to AGM Notice of Meeting dated 21 April 2026.</td></tr>
<tr><td>No. of securities held after change

David Ayers Hinton and Heather Joy Hinton <Bromilow Account> of which Mr Hinton is a trustee and beneficiary

David Ayers Hinton</td><td>- 430,000 Ordinary Fully Paid Shares
- 3,000,000 unlisted options with an exercise price of $0.02 expiring 26/06/2028
- 1,500,000 Performance Rights

- 2,000,000 Performance Rights</td></tr>
<tr><td>Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</td><td>Issue of Performance Rights as approved at the Annual General Meeting on 21 May 2026.</td></tr>
</table>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**HERAMED LIMITED**
ABN	**65 626 295 314**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sharon Richardson
Date of last notice	27 April 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct/Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Sharon A. Richardson as trustee for the Richardson Living Trust of which Dr Richardson is a trustee and beneficiary
Date of change	9 June 2026
No. of securities held prior to change Sharon A. Richardson	3,637,503 fully paid ordinary shares 2,000,000 unlisted options with an exercise price of $0.03 and expiry of 20 February 2029 3,000,000 unlisted options with an exercise price of $0.0528 and expiry date of 18 months from vesting
Class	Unlisted options with an exercise price of $0.0461:

Number of Unlisted Options	Vesting Condition	Exercise Date – Exercise no later than
800,000	20 day VWAP of $0.08 (8 cents) on or before the date that is 12 months from issue.	18 months from vesting
800,000	20 day VWAP of $0.12 (12 cents) on or before the date that is 24 months from issue.	18 months from vesting

800,000	The Company announcing to ASX that HeraCARE has reached not less than 2,000 active paid users at any time on or before 31 December 2027.	18 months from vesting
800,000	The Company announcing to ASX that HeraCARE has reached not less than 8,000 active paid users at any time on or before 31 December 2028.	18 months from vesting
800,000	The Company announcing to ASX that HeraCARE has reached not less than 20,000 active paid users at any time on or before 31 December 2029.	18 months from vesting

Number acquired	4,000,000 Unlisted Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Refer to AGM Notice of Meeting released on 21 April 2026.
No. of securities held after change Sharon A. Richardson Sharon A. Richardson as trustee for the Richardson Living Trust	 3,637,503 fully paid ordinary shares 2,000,000 unlisted options with an exercise price of \$0.03 and expiry of 20 February 2029 3,000,000 unlisted options with an exercise price of \$0.0528 and expiry date of 18 months from vesting 4,000,000 unlisted options with an exercise price of \$0.0461 and expiry 18 months from vesting.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Options as approved at the Annual General Meeting on 21 May 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.